NEW YORK (GenomeWeb News) – Atossa Genetics said today that it has signed up Millennium Healthcare to distribute its non-invasive breast cancer diagnostic test in the New York metro area and in northern New Jersey.

Under the agreement, Millennium Medical Devices will distribute and market Atossa's ForeCYTE Breast Health devices to managed-care networks, healthcare clinics, and physician practices.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.